Publicité

Médecine

Paramédical

Autres domaines


S'abonner

Association of CASP7 Polymorphisms and Survival of Patients With Non-small Cell Lung Cancer With Platinum-Based Chemotherapy Treatment

Doi : 10.1378/chest.11-2522 

Ji Qian a, Shaohua Gu a, Qihan Wu b, Xueying Zhao a, Wenting Wu a, Zhiqiang Gao c f, Wei Zhang c, Xiaoming Tan d e, Haijian Wang a, Jiucun Wang a, Weiwei Fan a, Hongyan Chen a, Baohui Han c, Daru Lu a * , Qingyi Wei f, Li Jin a

Voir les affiliations

Résumé

Background

CASP7 plays a crucial role in cancer development and chemotherapy efficacy. We, therefore, explored whether single nucleotide polymorphisms (SNPs) of the CASP7 gene can modulate outcomes of patients with advanced non-small cell lung cancer (NSCLC) treated with first-line platinum-based chemotherapy.

Methods

We systematically genotyped 17 SNPs of CASP7 first in a discovery set of 279 patients with advanced NSCLC treated with platinum-based chemotherapy and then replicated the results in an independent set of 384 patients, in whom we evaluated associations with overall survival (OS) and progress-free survival (PFS) by Kaplan-Meier analysis and Cox hazards regression analysis.

Results

In both discovery and validation sets as well as in the pooled analysis, heterozygotes of CASP7 rs2227310 and rs4353229 as well as rs12415607 variant allele were strongly associated with a better OS of NSCLC (in the pooled sample: adjusted hazard ratio [HR], 0.73; 95% CI = 0.59–0.90; P = .003; HR, 0.72; 95% CI = 0.59–0.89; P = .002; and HR, 0.76; 95% CI = 0.62–0.94; P = .009; respectively). In stratified analyses of the pooled data set, treated with paclitaxel, individuals carrying variant allele of rs2227310, rs4353229, and rs12415607 had significantly improved OS (HR, 0.60; 95% CI = 0.41–0.87; P = .008; HR, 0.58; 95% CI = 0.39–0.84; P = .004; and HR, 0.61; 95% CI = 0.42–0.89; P = .010; respectively).

Conclusions

This study provides evidence that genetic variations of CASP7 may modulate OS and PFS of patients with advanced NSCLC treated with platinum-based chemotherapy.

Plan


 Reproduction of this article is prohibited without written permission from the American College of Chest Physicians. See online for more details.
Funding/Support: This work was supported by the National Basic Research Program (973 program) of China [Grant 2011CB503802]; Shanghai Science and Technology Research Program [Grant 06DZ19501]; National Natural Science Foundation of China [Grants NSFC 81172093 and 30890034]; the Shanghai Pujiang Program [Grant 11PJD005]; and the China Ministry of Health [Grant 201002007].


© 2012  The American College of Chest Physicians. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer

Vol 142 - N° 3

P. 680-689 - septembre 2012 Retour au numéro
Article précédent Article précédent
  • Acute Pulmonary Admissions Following Implementation of a National Workplace Smoking Ban
  • Brian D. Kent, Imran Sulaiman, Trevor T. Nicholson, Stephen J. Lane, Edward D. Moloney
| Article suivant Article suivant
  • Pulmonary Embolism : The Weekend Effect
  • Rahul Nanchal, Gagan Kumar, Amit Taneja, Jayshil Patel, Abhishek Deshmukh, Sergey Tarima, Elizabeth R. Jacobs, Jeff Whittle, from the Milwaukee Initiative in Critical Care Outcomes Research (MICCOR) Group of Investigators

Bienvenue sur EM-consulte,
la référence des professionnels de santé.

Plus de 500 000 articles médicaux,
paramédicaux et scientifiques vous attendent.

Déjà abonné à cette revue ?

Publicité